Initial Treatment Approach for Idiopathic Inflammatory Myopathy

Introduction to Treatment

The American College of Rheumatology recommends that adult patients with idiopathic inflammatory myopathy (IIM) should receive high-dose corticosteroids concurrent with a steroid-sparing agent such as methotrexate, azathioprine, or mycophenolate mofetil, followed by a tapering course of corticosteroids 1, 2

Initiate prednisone at 0.5-1 mg/kg per day (typically 60-80 mg/day as a single daily dose) and begin tapering after 2-4 weeks depending on patient response, with a tapering schedule of 10 mg every 2 weeks until reaching 30 mg/day, then 5 mg every 2 weeks until reaching 20 mg/day, and further slowing to 2.5 mg every 2 weeks until completed 3

Start steroid-sparing agents at the same time as corticosteroids to reduce steroid-related morbidity, with options including methotrexate, azathioprine, and mycophenolate mofetil, which typically take 3-6 months to reach full efficacy 3
Methotrexate should be begun at 25-50 mg/week with increments of 25-50 mg/week until reaching goal dosage, while azathioprine should be started after checking thiopurine methyltransferase level, with a target dosage of 2 mg/kg of ideal body weight in divided doses 3
Mycophenolate mofetil is particularly useful for patients with IIM-associated interstitial lung disease 1, 3

For patients with severe myositis, extensive extramuscular involvement, or refractory disease, treatment should include high-dose intravenous methylprednisolone plus one of the following: intravenous immunoglobulin, cyclophosphamide, rituximab, or cyclosporine 1, 2, 4

Monitor muscle strength, creatine kinase levels, and functional capacity, and consider using MRI to assess muscle inflammation and treatment response, as well as novel biomarkers such as interleukin-6 and type 1 interferon-regulated genes as indicators of disease activity 1, 3, 5

Monitor bone health with dual-energy x-ray absorptiometry and prescribe calcium and vitamin D supplements, with bisphosphonate added if osteoporosis is present, and consider Pneumocystis prophylaxis and updating vaccines before starting immunosuppressants 4, 6

Juvenile dermatomyositis treatment differs slightly, with corticosteroids at 2 mg/kg (max 60 mg/day) and subcutaneous methotrexate (15 mg/m² weekly) 1, 7
Immune-mediated necrotizing myopathy may require more aggressive immunosuppression 7